Objective

Novo Nordisk, founded in 1923 and headquartered in Bagsværd, Denmark, is a leading global healthcare company specializing in treatments for serious chronic diseases such as diabetes and obesity. With a workforce of approximately 77,000 employees, the company markets its products in around 170 countries. In 2024, Novo Nordisk reported net sales of DKK 290.4 billion, reflecting a 25% increase from the previous year. The company's portfolio includes notable products like Ozempic® (semaglutide), which has demonstrated significant weight loss benefits in clinical trials. Novo Nordisk continues to focus on innovation, as evidenced by its recent partnership with Valo Health to develop novel treatments for cardiometabolic diseases.

Contexts

• #LAS-case-study